Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-RESERP vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.
250 mg orally twice daily
50-100 hours (terminal); prolonged in renal impairment, leading to accumulation on repeated dosing.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Hydrochlorothiazide is not extensively metabolized; it is excreted unchanged in urine. Reserpine is extensively metabolized in the liver by hydrolysis and conjugation.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal: 30-40% as unchanged reserpine; biliary/fecal: 60-70% as metabolites.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
96% bound to albumin and alpha1-acid glycoprotein.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
1.5-2.5 L/kg; extensive tissue distribution with high affinity for adrenergic neurons.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 50-60% (first-pass metabolism); IM: ~100%.
70-90% (oral); 100% (IV).
Contraindicated if e GFR <30 m L/min/1.73m² due to HCTZ ineffectiveness. For GFR 30-50 m L/min: reduce HCTZ to 12.5-25 mg daily; reserpine unchanged. Monitor serum creatinine and electrolytes. Not recommended for anuric patients.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment. Child-Pugh B: reduce HCTZ by 25-50% (start at 12.5 mg) due to risk of electrolyte imbalance; reserpine: use lowest effective dose (0.125 mg) and monitor for encephalopathy. Child-Pugh C: avoid HCTZ; reserpine contraindicated due to risk of hepatic coma.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not approved for pediatric use. Limited data: HCTZ 1-2 mg/kg/day orally once or divided; max 50 mg/day. Reserpine 0.01-0.02 mg/kg/day in 1-2 doses; max 0.25 mg/day. Monitor growth, electrolytes, and blood pressure closely in children.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at half the adult dose: HCTZ 12.5 mg orally daily; reserpine 0.05-0.1 mg daily. Titrate slowly (every 2-4 weeks). Monitor for orthostatic hypotension, electrolyte disturbances, depression (reserpine), and dehydration. Avoid in frail elderly due to increased fall risk.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
Reserpine may cause mental depression, especially in patients with a history of depression. Risks are dose-related and may persist after discontinuation. Use with caution or avoid in patients with a history of depression.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause depression with suicidal risk (reserpine).,May cause electrolyte imbalances (hypokalemia, hyponatremia) due to hydrochlorothiazide.,May increase serum uric acid and precipitate gout.,May cause orthostatic hypotension and bradycardia.,Use cautiously in patients with renal impairment or hepatic disease.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to hydrochlorothiazide, reserpine, or sulfonamide derivatives.,History of depression (especially with reserpine).,Active peptic ulcer or ulcerative colitis (reserpine).,Electroconvulsive therapy (within 1 week).,Severe renal impairment (anuria) or severe hepatic disease.,Pregnancy (especially in second and third trimesters; avoid use).
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-sodium foods to reduce blood pressure; limit alcohol consumption. Avoid excessive intake of tyramine-rich foods (e.g., aged cheeses, cured meats, fermented foods) as reserpine may potentiate pressor response; however, risk is low with reserpine compared to MAOIs. Maintain potassium-rich diet if hypokalemia risk exists (e.g., bananas, oranges, spinach).
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Reserpine crosses the placenta. First trimester: limited human data but animal studies suggest risk; consider alternative if possible. Second/third trimester: may cause neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion. Avoid in preeclampsia due to risk of placental hypoperfusion. Risk category C.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Reserpine is excreted into breast milk. M/P ratio approximately 1.6. Potential for infant bradycardia, nasal congestion, and lethargy. Contraindicated in nursing mothers due to risks.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No specific dose adjustments based on pharmacokinetic changes in pregnancy. Use lowest effective dose to minimize fetal risk.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Hydro-Reserp combines hydrochlorothiazide and reserpine; reserpine depletes catecholamines, which may cause depression and sedation. Monitor for orthostatic hypotension and electrolyte imbalances. Avoid in patients with history of depression or peptic ulcer disease. Use with caution in patients with renal impairment.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take this medication exactly as prescribed; do not stop abruptly.,May cause drowsiness or dizziness; avoid driving or operating machinery if affected.,Stand up slowly from sitting or lying down to prevent falls.,Report any signs of depression, unusual mood changes, or slow heartbeat.,Avoid excessive sun exposure; may increase sensitivity to sunlight.,Do not use alcohol while taking this medication.,Monitor blood pressure regularly and keep follow-up appointments.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-RESERP vs ALDOCLOR-250, answered by our medical review team.
HYDRO-RESERP is a Antihypertensive Combination that works by Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-RESERP and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-RESERP is: HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-RESERP and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-RESERP is classified as Category C. Reserpine crosses the placenta. First trimester: limited human data but animal studies suggest risk; consider alternative if possible. Second/third trimester: may cause neonatal re. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.